ArticleClinical breast cancer2018

A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.

Autumn J McRee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.